Medscape www.medscape.com

References for:
Tumors and Solid Organ Transplantation: Intersections at Multiple Levels

[Medscape Transplantation 4(1), 2003. © 2003 Medscape]

  1. Buell J. Israel Penn International Transplant Tumor Registry. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  2. Feng S, Buell JF, Cherikh WS, et al. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation. 2002;74:1657-1663. Abstract
  3. Jacobs S. The impact of urological malignancies. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  4. Chin LT. Organs (especially kidneys) from donors with renal cell carcinoma: should be used. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  5. Sagalowsky A. Organs (especially kidneys) from donors with renal cell carcinoma: Should be not used. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  6. Holland E. CNS malignancies are different, right? Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  7. Geissler E. mTOR inhibition: a treatment strategy targeting both rejection and tumors in transplant patients with cancer. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  8. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135. Abstract
  9. Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74:1409-1413. Abstract
  10. Adams R. The impact of breast or colon cancer. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  11. Kauffman HM. UNOS Tumor Registry. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  12. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74:358-362. Abstract
  13. Woodle ES. Post-transplant outcomes for recipients with previous cancer: IPITTR. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  14. Port F. Standardization incidence ratio: the rate of de novo malignancies by site and transplanted organ compared to population-based controls. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  15. Hariharan S. Evaluation of candidates with a history of cancer. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  16. Otley C. Skin cancer in organ transplant recipients: challenges and opportunities. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  17. The International Transplant Skin Cancer Collaborative. Available at: http://www.itscc.org. Accessed February 14, 2003.
  18. Salasche S. Are certain skin malignancies prohibitive for organ transplantation? Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  19. UNOS MELD information for transplant recipients. Available at:
  20. http://www.hepatitis-central.com/hcv/liver/MELD_20020213_Brochure_DCS.pdf. Accessed February 14, 2003.
  21. Freeman R. Impact of MELD on OLTx for HCC. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  22. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699. Abstract
  23. Marsh W. Staging systems for hepatocellular carcinoma. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  24. Rosen C. Cholangiocarcinoma and liver transplantation: transplantation is indicated. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  25. Pinson CW. Cholangiocarcinoma and liver transplantation: transplantation is never indicated. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  26. DiMaio JM. The Marlboro Man and transplantation. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  27. Kiberd B. Screening for de novo cancer in transplant recipients: no additional screening is needed. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  28. Bennett W. Screening for de novo cancer in transplant recipients: escalated screening is indicated and necessary. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  29. Greenberg P. Attack of the killer clones: using T cells to treat human viral and malignant diseases. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  30. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest. 2002;110:1415-1417. Abstract
  31. Sligh J. Human papilloma virus: Is viral status a predictor or a risk factor for cancer? Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  32. Ganem D. Rethinking the pathogenesis of Kaposi's sarcoma. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  33. Chari R. What mice can teach us about HCC. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  34. Rooney C. The biology of Epstein Barr virus. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  35. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002;118:728-740. Abstract
  36. Nalesnik M. What is and what is not PTLD? Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  37. Transplant Pathology Internet Services. Available at: http://tpis.upmc.edu/tpis/main.html. Accessed February 14, 2003.
  38. Hanto D. Impact of PTLD classification on treatment. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  39. Green M, Webber SA. EBV viral load monitoring: unanswered questions. Am J Transplant. 2002;2:894-895. Abstract
  40. Gross T. 'CHOP Lite.' Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.
  41. Gross TG. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. Recent Results Cancer Res. 2002;159:96-103. Abstract
  42. Liu Z, Savoldo B, Huls H, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002;159:123-133. Abstract
  43. Brenner M. Potential applications of adoptive immunotherapy for PTLD after solid organ transplantation. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, 2003; Miami, Florida.